Weekly Quick Hits (BioHealth Capital Region) – Week of May 29, 2023

Published on :

Weekly Quick Hits (BioHealth Capital Region) – Week of May 29, 2023 By Sarah EllinwoodJune 2, 2023 Funding, Awards and Collaborations BCWorld Healthcare and ReGelTec Enter Exclusive Distribution Agreement for [….]

Weekly Quick Hits (BioHealth Capital Region) – Week of May 22, 2023

Published on :

Weekly Quick Hits (BioHealth Capital Region) – Week of May 22, 2023 By Sarah EllinwoodMay 26, 2023 Funding, Awards and Collaborations Adaptive Phage Therapeutics Partners with Hebrew University, Hadassah Medical [….]

Medcura Receives Breakthrough Device Designation for its LifeGel™ Absorbable Surgical Hemostat

Published on :

Medcura, Inc., a medical device company dedicated to transformatively improving the management of surgical bleeding, announces that the U.S. Food and Drug Administration (FDA) has granted the coveted Breakthrough Device Designation for its LifeGel™ Absorbable Surgical Hemostat. LifeGel™ is the first and only hemostatic agent to receive Breakthrough Device Designation seeking a new and highly differentiated indication: in surgical procedures (except in ophthalmic and urological) as an adjunctive hemostatic device when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical. Due to its no-swell properties, LifeGel can be used in surgical procedures where swelling cannot be tolerated.

TEDCO Invests First of Maryland’s SSBCI Funds in Medcura, Inc.

TEDCO logo over a backdrop of the Maryland flag
Published on :

TEDCO, Maryland’s economic engine for technology companies, announced today it invested $1 million in Medcura, Inc. through the new State Small Business Credit Initiative (SSBCI). Based in Riverdale, MD, Medcura is a life science and medical device company that has commercialized its first product derived from its advanced wound treatment platform for rapid bleeding management and is in the final stages of development of the next standard of care for the management of intraoperative surgical bleeding.

Medcura Expands its Senior Leadership Team and Appoints Leading Neurosurgeon Dr. Kenneth Renkens as Chief Medical Officer

Published on :

Medcura, Inc., a commercial-stage medical device company, today announced the expansion of its senior management team to include Dr. Kenneth Renkens as its Chief Medical Officer. Dr. Renkens is a thought-leading neurosurgeon who co-founded the Indiana Spine Group and has been involved in the development and commercial success of numerous innovative products now widely used in operating rooms around the world.